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Anti-idiotypic antibodies  have  been  used  in  various  systems  to  study  both  the 
spectrum of the immune response (1) and the nature of cellular receptors to antigens 
(2).  Because of the evidence that  idiotypic determinants can be associated with the 
antigen-combining site (3), idiotypy of antibody may be used as a  mirror image for 
defining antigenic determinants of molecules otherwise difficult to elucidate. More- 
over,  the  demonstration  of idiotypic markers  on  lymphocyte receptors  (2)  suggests 
that  anti-idiotypic  (anti-receptor)  antibodies can  be  used  for  functional  studies  of 
immune recognition. 
Ia  molecules,  HLA-DR  in  man,  are  an  extensively polymorphic  family of cell- 
surface antigens of key importance in regulating antigen responsiveness and immune 
cell cooperation (4).  From studies in the mouse system  (5), it appears that single Ia 
antigenic determinants  can  affect  recognition events  and  immune  performance.  In 
man,  the  definition  of single Ia  determinants  cannot  be  achieved  through  genetic 
recombination or isolation of mutant  strains, as in the mouse,  thus  posing a  major 
problem for the functional study of Ia antigens. 
We  describe here  an  initial investigation of the  idiotypes of murine  monoclonal 
antibodies (mAb)  to human  Ia antigens, in an effort to define Ia determinants  and 
their cellular interaction pathways. 
Materials  and  Methods 
Monoclonal Antibodies.  Monoclonal antibodies to human Ia (HLA-DR) antigens are listed in 
Table I. Monoelonal antibodies to HLA-A,B antigens Q1/28  (6),  Q6/64  (7),  and W6/32  (8) 
have  been  previously described. W6/32  was  a  kind  gift of Dr.  Peter  Parham.  The  mouse 
myeloma protein MOPC21  was obtained from ascites of BALB/c mice carrying intraperito- 
neally the mouse myeloma line P3X63Ag8. 
Cells.  Ia-positive human  B  lymphoblastoid cell lines  LG-2  (HLA-DR1),  Daudi  (HLA- 
DRW6), and WI-L2 (HLA-DR4,7) were cultured in RPMI  1640  media supplemented with 
10% fetal calf serum, 2 mM glutamine, and 50/~g/ml gentamicin. 
Anti-Idiotypic Sera.  A New Zealand white rabbit was immunized with purified mAb Q5/13 
(IgG2a,k) (9), as described (10).  The immune serum was sequentially absorbed over a pooled 
normal mouse gamma globulin immunoadsorbent and an mAb Q1/28  (IgG2a,k) immunoad- 
sorbent. The  absorption procedure was  repeated three times, at  a  ratio of 5  ml  of packed 
immunoadsorbent beads per 10 ml of serum. 
Binding Assay.  Polyvinyl microtiter wells (Dynatech Corp., Alexandria, VA) coated with 
either purified mAb or immunoglobulins were incubated at 4°C overnight with 50/~1 of serum 
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Competitive in-  Inhibition of 
hibition of bind-  Donor mouse  Refer-  binding to Ia  + 
strain  Source  ing of HP-Q5/  cells by anti-  ence  13 to anti- 
idiotype 3496  idiotype  3496* 
Q2/47  Monomorphic 
Q2/70  Monomorphic 
Q2/80  Monomorphic 
Q5/13  Monomorphic 
Q6/22  Monomorpbic 
417.1  Monomorphic 
S 1.5/1  Monomorphic 
S 1.19/9  Monomorphic 
T2143  Monomorphic 
T2171  Monomorphic 
T2172  Monomorphic 
SCX7  Monomorphic 
L203  Monomorphic 
L243  Monomorphic 
OKIa2  Monomorphic 
CA2.206  Monomorphic 
DR.2  Monomorphic 
NE 1-01 l  Monomorphic 
DA.2  Monomorphic 
Genox 3.53  DR 1,2,W6 
MRC.OX3  DR 1,2,W6 
MCLB.8  Neg to DR3,5,7 
Q5/6  Neg to DR7 
E3.15/4  DR3,5,W6 
NZB/W  V. Quaranta  9  --  --~: 
NZB/W  V. Quaranta  9  -- 
NZB/W  V. Quaranta  9  95  -- 
BALB/c  V. Quaranta  9  95  98 
BALB/c  V. Q uaranta  9  --  -- 
BALB/c  G.A. Mnlinaro  --  95  98 
DBA2/J  M. Trucco  20  --  -- 
DBA2/J  M. Trucco  20  --  -- 
BALB/c  R.F. Fox  21  -- 
BALB/c  R.F. Fox  21  --  -- 
BALB/c  R.F. Fox  21  --  -- 
BALB/c  R.F. Fox  21  --  -- 
BALB/c  R. Levy  22  --  -- 
BALB/c  R. Levy  22  --  -- 
--  Ortho  --  --  -- 
BALB/c  H.O. McDevitt  23  62§  54 
BALB/c  BRL  24  --  -- 
B6 × BALB/c  NEN  25  --  -- 
BALB/c  F.M. Brodsky  8  --  -- 
C3H  F.M. Brodsky  8  --  ND]] 
--  F.M. Brodsky  26  --  ND 
--  F.M. Brodsky  27  --  -- 
BALB/c  V. Q uaranta  9  --  -- 
BALB/c  M. Trucco  20  --  -- 
* These tests were performed as described in Materials 
Daudi, and WI-L2. 
:~ No detectable inhibition. 
§ Inhibition caused by 100 ng of purified antibody. 
II Not done. 
and Methods with three human B lymphoblastoid cell lines, LG-2, 
3496,  appropriately diluted.  After washing, the wells were incubated at 4°C for 3  h  with l~sI- 
labeled  sheep  IgG  anti-rabbit  Fc,  then  washed  extensively,  and  radioactivity  bound  was 
determined with a  gamma counter. The binding of preimmune serum to Q5/13 was used as a 
background control. 
Inhibition of Binding to Target Cells.  A  previously determined  limiting dilution  of mAb  (25 
#1)  was incubated  overnight with either serial  dilutions of antiserum 3496  (25 #1)  or normal 
serum (25 #1) and then added to microtiter wells coated with human cells WI-L2 (5 ×  104 cells/ 
well) by drying overnight at 37°C. After 1 h  at 4°C, the plate was washed and incubated with 
50/~1  of an optimal dilution of horse-radish peroxidase (HP)-conjugated rabbit anti-mouse Ig 
(Tago,  Inc.,  Burlingame,  CA),  for  1  h  at  4°C.  Bound  peroxidase  activity  was  revealed  by 
addition of o-phenylenediamine and H202.  The reaction was stopped after 30 min in the dark 
by 4  M  HzSO4,  and optical  absorbance was determined at  492  nm with a  Multiskan  ELISA 
reader (Flow Laboratories, Inc., Inglewood, CA). Incubation of Q5/13 with preimmune serum 
3496 was used as a  further control. Results are expressed as percent inhibition:  100 -  ([average 
A492 of duplicate wells in which 3496  plus mAb were tested]  ×  100/average A492 of duplicate 
wells  in  which normal  rabbit  serum plus mAb were tested).  In  the  latter  wells, A492 ranged 
between  0.200  and  0.800,  with  a  background  of 0.020.  Phosphate-buffered  saline,  pH  7.4, 
containing 0.5% Tween 20 and 2% bovine serum albumin was used throughout the assays. 
Competitive Inhibition Assays.  mAb  Q5/13  conjugated  to  HP  (HP-Q5/13)  was  prepared 
according to Harper and Orengo (11). 
Inhibition of Binding of Q5/13 to Anti-Idiotypic Serum 3496 by Human Ia Molecules.  A  limiting 
dilution  of HP-Q5/13  was mixed  in  a  final  volume of 50  /~1  with  the  indicated  amounts of 
either  immunologically  active  human  Ia  molecules  purified  by  high  performance  liquid 
chromatography (L. E. Walker, unpublished data) or purified fl~-microglobulin (Immunochem- 
ical Engineering, Inc., Minneapolis, MN). After incubating overnight at 4°C, the mixture was 
allowed to react at 4°C for 3 h  in wells coated with anti-idiotypic serum 3496 diluted  1/2,000. QUARANTA ET AL.  BRIEF  DEFINITIVE REPORT  1553 
After extensive washing, the bound HP activity was measured  as described above. Tests were 
done in triplicate.  Results are expressed as percent  inhibition  of the binding of HP-Q5/13 in 
the presence of Ia molecules, as compared with the maximum binding observed  in wells to 
which  no inhibitor  was added.  In the wells lacking  inhibitor,  A492 averaged  0.400, i.e., >10 
times the reading of blank background wells. 
Inhibition  of Binding  of Q5/13  to  Anti-ldiotypic  Serum 3496  by  Other rnAb.  This  assay  was 
performed as described above, with the following modifications:  25 #1 of a limiting dilution  of 
HP-Q5/13 was mixed with an equal amount of mAb (either ascites fluid or 10 × concentrated 
hybridoma supernatant)  rather  than  with  purified  Ia.  The  first overnight  incubation  was 
omitted.  Most of the antibodies obtained from other laboratories were understandably received 
in limited quantities and in a nonpurified form, either as ascitic fluid or hybridoma supernatant; 
consequently, it was not possible to test them quantitatively.  However, because stoichiometry 
of idiotype-anti-idiotype  binding indicated  that  1 ng of Q5/13  idiotype  could induce  50% 
inhibition of  binding (data not shown), we estimate that each mAb was tested at a concentration 
at least 100-fold greater than that of Q5/13 idiotype. 
Results and Discussion 
Rabbit  antiserum  3496 to the murine mAb Q5/13, specific for HLA-DR mono- 
morphic  determinants,  was  effectively  rendered  idiotype  specific  by  appropriate 
absorptions as  it  markedly bound to Q5/13,  but  failed  to react  with either  pooled 
normal mouse gamma globulin or antibodies sharing isotype, allotype, or MOPC21 
determinants with Q5/13. 
Idiotypic determinants recognized by this antiserum were shown to be associated 
with the antigen-combining site of Q5/13 by the results of two independent  sets  of 
experiments:  (a)  anti-idiotypic antibodies were able to completely block the binding 
of Q5/13  to  Ia-positive  target  cells  (Fig.  l a);  (b)  conversely,  purified  human  Ia 
molecules inhibited  the binding of enzyme-linked Q5/13 to microtiter wells coated 
with  anti-idiotype  3496  (Fig.  1 b).  In  both  instances,  the  inhibitions  were  specific 
because antiserum 3496 did not affect the binding of HLA-A,B monoclonal antibodies 
to target cells, and the binding of Q5/13 to anti-idiotype 3496 was not diminished by 
either a  control protein  (Fig.  1 b)  or cell  lysates from Ia-negative human lymphoid 
cells  (data not shown). 
We examined the presence of Q5/13 idiotype on other anti-Ia mAb to ascertain the 
degree of idiotypic relatedness  among antibody molecules obtained  from different 
immunizations and fusion experiments.  As indicated in Table I, three mAb (417.1, 
CA2.206, and Q2/80), when tested  for competitive inhibition of binding of Q5/13 
idiotype  to  anti-idiotype  3496,  were  found to  be  inhibitory and,  therefore,  shared 
idiotype with Q5/13.  These mAb were all directed against  monomorphic Ia deter- 
minants.  In  contrast,  none  of five  mAb  directed  to  Ia  polymorphic  specificities 
inhibited  the  binding  reaction  (Table  I).  Inhibition  by  mAb  CA2.206  was  not 
complete, even with  100-fold excess  amounts, indicating only partial  idiotype cross- 
reactivity with  Q5/13.  Interestingly,  not  only were  the  four mAb  bearing  similar 
idiotypes obtained  in  distinct  fusion experiments,  but  in  one  instance,  Q2/80,  the 
donor mouse was of NZB/W strain, as opposed to the BALB/c strain donors for the 
other three antibodies. 
To confirm and further define the idiotype cross-reactivities observed, we tested the 
ability of antiserum  3496  to  inhibit  the  binding of mAb to  target  cells  (Table  I). 
Thus,  the  binding of both  mAb 417.1  and  CA2.206 was  inhibited,  the  latter  to  a 
similar extent as in the competitive binding assay, demonstrating sharing of idiotype 
at the level of the antigen-combining site.  In contrast, the binding of Q2/80 to target 
cells  was not affected by antiserum 3496, indicating that this assay system is highly 1554  QUARANTA ET AL. 
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FIc.  i.  (a) Inhibition of binding to Ia-positive human B lymphoblastoid cell lines by anti-idiotype 
serum 3496. Tested mAb are anti-la  Q5/13 (O  O), anti-HLA-A,B (211/28 (I-1  V]), W6/32 
(0  0),  and Q6/64  (A  A).  Background activity by preimmune serum on Q5/13  is also 
indicated (O-----O). (b) Competitive inhibition of the binding ofQ5/13 to anti-idiotype serum 3496 
by purified human Ia molecules (O  O) and control fl2-microglohulin (A  ..... A). 
discriminating  and  that  Q2/80  bears  a  Q5/13  idiotype, however, not in association 
with its antigen-combining site. 
These data are consistent with the possibility that the mouse antibody response to 
human  Ia  antigens  is  based  upon  a  discrete  number  of recurrent  idiotypes.  This 
interpretation needs to be confirmed by examining the idiotypes of those anti-Ia mAb 
that do not bear the Q5/13  idiotype. It is possible that the techniques that are used 
to generate hybridomas may introduce a bias towards certain idiotypes; however, this 
does not seem to be the case here because preliminary data indicate that the Q5/13 
idiotype  is  found  as  a  significant  component  in  the  serum  of both  BALB/c  and 
NZB/W mice immunized against human Ia-positive cells, 
Results  similar  to ours have been  reported  in  the  homologous murine  Ia system. 
Thus,  the  idiotype  of a  mAb  to  Ia.7,  a  monomorphic  specificity  of murine  I-E 
molecules,  was  readily  detectable  in  anti-Ia.7  alloantisera  (12).  Similarly,  idiotypic 
cross-reactivity among mAb directed to monomorphic but not polymorphic specific: 
ities of Ia  k has been recently reported (13). Taken together, these observations suggest 
that  Ia monomorphic determinants  stimulate  antibody-forming cells  displaying  re- 
lated idiotypes. 
It  is  tempting  to propose that  mAb Q5/13,  417.1,  and  CA2.206  define  a  mono- 
morphic  Ia specificity because  their  shared  idiotype  is  associated  with  the  antigen- 
combining  site.  However,  one  has  to  critically  evaluate  this  conclusion  because  a 
shared idiotype at the level of the antigen-combining site may (3,  14,  15) or may not 
(16,  17) relate directly to a particular epitope specificity. Conversely, idiotype sharing 
between Q5/13 and Q2/80, restricted to determinants outside the antigen-combining 
site,  does not  definitively rule out  the possibility that  Q5/13  and  Q.2/80  may react 
with a  similar Ia antigenic site.  Verification of such an association in the human Ia 
system  is  especially  hampered  by  the  lack  of definition  of private  and  public  Ia 
specificities.  Nevertheless,  by  using  Western  blotting  techniques,  we  demonstrated 
additional  similarities  among the reactivity patterns  of Q5/13,  417.1,  and CA2.206, 
i.e., they all react with an epitope that is located on the Ia fl subunit  and is resistant 
to subunit dissociation (V. Q uaranta, unpublished work). Because of their differential 
reactivity with antiserum 3496 (See Table I), Q5/13 and CA2.206 may be directed to QUARANTA ET AL.  BRIEF  DEFINITIVE REPORT  1555 
overlapping but not identical antigenic sites. 
The frequency of the Q5/13 idiotype among anti-Ia mAb from separate immuni- 
zations may either be the effect of human Ia molecule domains immunodominant to 
the  mouse antibody response  or  it  may represent  an  integral  part  of a  regulatory 
idiotype pathway  (18)  in  the  mouse immune system.  Determining whether or not 
mAb Q5/13, 417.1, CA2.206, and Q2/80 react with the same or similar epitopes will 
help in distinguishing between these two alternatives.  It is possible that both of them 
might turn out to be correct. 
A  potential  application of anti-idiotypic serum  3496 is as a  probe of recognition 
units for Ia antigens on T  cells.  Thus,  the role of Ia monomorphic determinants  in 
immune cell interplays could be elucidated. In this regard, it is relevant that Q5/13 
has an inhibitory effect both on allogeneic and autologous mixed lymphocyte reactions 
(19).  Consequently, alloreactive and  autoreactive T  cells  may recognize the Q5/13 
monomorphic  determinant  and  possibly  bear  idiotypic  structures  similar  to  the 
Q5/13 idiotype. 
Summary 
We report  a  recurrent  idiotype on a  remarkably high  fraction  (4/19)  of murine 
monoclonal antibodies specific for human Ia monomorphic determinants and elicited 
by separate immunizations. For three of them, the shared idiotype is associated with 
the antigen-combining site. These results indicate that the spectrum of mouse antibody 
responses  to human Ia antigens may be  based on recurrent  idiotypes, suggesting a 
limited potential repertoire of murine monoclonal antibodies to human Ia antigens. 
Anti-idiotypic reagents might be helpful in dissecting this repertoire and to generate 
a  mirror image of a  human Ia antigenic map. Furthermore, antisera to the idiotype 
of  antibodies  specific  for  human  Ia  monomorphic  determinants  might  help  in 
elucidating the interactions between Ia molecules and receptors on immune cells. 
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Systems, Westwood, MA; BRL, Inc., Rockville, MD, and New England Nuclear,  Boston, MA, 
for their  kindness in  providing us with  monoclonal  antibodies.  We are  thankful  to Natalia 
Tseytlin  and  Michael  Walsh  for expert  technical  assistance, and  to Bonnie  Filiauh  for her 
expertise in typing this manuscript. 
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